Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

6-month HIV PrEP makes coverage gains with insurers

Summary
Six months after its approval by the Food and Drug Administration (FDA), the latest advancement in HIV pre-exposure prophylaxis (PrEP) is gaining coverage from insurers initially weary of its high price tag. The FDA approved Yeztugo, a 6-month biannual HIV PrEP injection, in June of last year. But health insurers were openly hesitant about covering the drug due to its annual cost of nearly $30,000.

1 Articles

The HillThe Hill
Center

6-month HIV PrEP makes coverage gains with insurers

Click in for more news from The Hill {beacon} Health Care Health Care   The Big Story  6-month HIV PrEP makes coverage gains with insurers Six months after its approval by the Food and Drug Administration (FDA), the latest advancement in HIV pre-exposure prophylaxis (PrEP) is gaining coverage from insurers initially weary of its high price tag.  © Gilead Sciences…

·Washington, United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

The Hill broke the news in Washington, United States on Thursday, January 29, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

FDA icon

FDA

US Politics icon

US Politics

Politics icon

Politics

Trump Administration icon

Trump Administration

Insurance icon

Insurance

Medical icon

Medical

HIV icon

HIV

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal